Armata Pharmaceuticals, Inc. - 8-K Filing
Armata Pharmaceuticals receives FDA agreement on Agreed Initial Pediatric Study Plan for AP-SA02 in complicated Staphylococcus aureus bacteremia. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ARMP